Ablynx clinical trials

Acquired by Sanofi, May 2018 · source ↗

The registry lists 25 studies whose lead sponsor is Ablynx. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 5, 2023.

Studies

Recruiting first, then most recently updated. Showing 25 of 25. All Sanofi studies →

• Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraCompletedNCT02553317Phase 3

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedNCT01151423Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) PatientsCompletedNCT01020383Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract InfectionCompletedNCT02979431Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid ArthritisCompletedNCT02287922Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid ArthritisCompletedNCT02309359Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid ArthritisCompletedNCT02518620Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract InfectionTerminatedNCT03418571Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) InfectionWithdrawnNCT03468829Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus ErythematosusCompletedNCT02437890Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171CompletedNCT02309320Phase 1/2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• ALX-0061 Phase I Bioavailability Study in Healthy VolunteersCompletedNCT02101073Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) PatientsCompletedNCT01284569Phase 1/2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• ALX-0171 Phase I Pharmacokinetic Study in Healthy Male VolunteersCompletedNCT01875926Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• ALX-0171 Safety Study in Adults With Hyperresponsive AirwaysCompletedNCT01909843Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male VolunteersCompletedNCT01483911Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.CompletedNCT03172208Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid ArthritisCompletedNCT01063803Phase 2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.CompletedNCT02189733Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid ArthritisCompletedNCT01007175Phase 1/2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy SubjectsCompletedNCT01284036Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy SubjectsCompletedNCT01401764Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid ArthritisCompletedNCT00959036Phase 1/2

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male SubjectsCompletedNCT00916110Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi

• First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4TerminatedNCT01374503Phase 1

  Sponsor listed in the registry: Ablynx, a Sanofi company · First submitted before Ablynx became part of Sanofi